HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.

Abstract
Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients with chronic renal failure. We investigated the effect of calcitriol, paricalcitol, and the calcimimetic AMG 641 on soft-tissue calcification in uremic rats with secondary hyperparathyroidism. Control and uremic rats were treated with vehicle, calcitriol, paricalcitol, AMG 641, or a combination of AMG 641 plus calcitriol or paricalcitol. Parathyroid hormone levels were reduced by all treatments but were better controlled by the combination of paricalcitol and AMG 641. The calcimimetic alone did not induce extraosseous calcification but co-administration of AMG 641 reduced soft-tissue calcification and aortic mineralization in both calcitriol- and paricalcitol-treated rats. Survival was significantly reduced in rats treated with calcitriol and this mortality was attenuated by co-treatment with AMG 641. Our study shows that extraskeletal calcification was present in animals treated with calcitriol and paricalcitol but not with AMG 641. When used in combination with paricalcitol, AMG 641 provided excellent control of secondary hyperparathyroidism and prevented mortality associated with the use of vitamin D derivatives without causing tissue calcification.
AuthorsI Lopez, F J Mendoza, E Aguilera-Tejero, J Perez, F Guerrero, D Martin, M Rodriguez
JournalKidney international (Kidney Int) Vol. 73 Issue 3 Pg. 300-7 (Feb 2008) ISSN: 0085-2538 [Print] United States
PMID18004298 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Calcium Channel Agonists
  • Ergocalciferols
  • Phosphorus
  • paricalcitol
  • Calcitriol
  • Calcium
Topics
  • Animals
  • Aorta (metabolism)
  • Calcinosis (complications, drug therapy, metabolism)
  • Calcitriol (therapeutic use)
  • Calcium (metabolism)
  • Calcium Channel Agonists (therapeutic use)
  • Ergocalciferols (therapeutic use)
  • Hyperparathyroidism, Secondary (complications, drug therapy, metabolism)
  • Male
  • Phosphorus (metabolism)
  • Rats
  • Rats, Wistar
  • Uremia (complications, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: